Introduction
Colorectal cancer is one of the most common malignant tumors in China and the Western world. Large-scale population studies have shown that hormone replacement therapy (HRT) significantly reduces the risk of colorectal cancer 1 . Though benefits of estrogen or progesterone are difficult to separate, the protective effects are seen in some observational studies with estrogen treatment alone 2 . These findings strongly indicate that estrogen may lower the risk of colorectal cancer. It has been shown in rodents and cell lines that estrogen induces apoptosis and inhibits proliferation of the intestinal epithelial cells 3, 4 .
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However, the mechanism by which estrogen enhances apoptosis and prevents colorectal carcinogenesis remains unclear.
The DNA mismatch repair (MMR) system consists of proteins that detect and repair nucleotide base mismatches and slippage mistakes on newly synthesized DNA at microsatellite sequences. It plays a key role in maintaining genomic stability. MMR dysfunction causes microsatellite instability (MSI). It has been reported that postmenopausal hormone replacement therapy reduces risks of only MSI-low/MSI-stable colorectal cancer subtypes, but not of MSI-high tumors 5, 6 . Moreover, estrogen receptor β (ERβ), the predominant ER in the human colonic epithelium 7 , has been indicated to have a protective role in colorectal cancer 8, 9 . These findings suggest that MMR proteins may participate in an estrogen-mediated protective effect on colorectal cancer.
In this study, we investigated the roles of two major MMR proteins, human mutL homolog 1 (hMLH1) and mutS homolog 2 (hMSH2), in the apoptosis of colon cancer cells and the involvement of estrogen in the processes. Two MMR-deficient human colon carcinoma cell lines were used: the hMLH1 deficient HCT116 cells containing a homozygous nonsense mutation at codon 252 (stop codon) in exon 9, and the hMSH2 deficient LoVo cells containing a homozygous deletion in the hMSH2 gene from exon 3 to exon 8 10 . The functions of the two MMR proteins in apoptosis were evaluated by overexpression of wild-type cDNA of hMLH1 and hMSH2, respectively, in HCT116 or LoVo in the presence and absence of estrogen. We demonstrated by both Western blot and FACS analysis that hMLH1 promote apoptosis that was further enhanced by estrogen. In addition, overexpression of hMSH2 or ERβ in HCT116 cells also promotes apoptosis, although the effects were estrogen-independent. We provide definite evidence that hMLH1 and hMSH2 exhibit similar yet distinctive role in estrogen-dependent and -independent apoptosis of colon cancer cells. Moreover, our studies of healthy post-menopausal female subjects demonstrated that 6-month HRT led to a significant elevation of hMLH1 expression and a concurrent increase in activation of caspase-3 and caspase-9 in the colonic mucosa.
Materials and Methods

Cell culture, transfection, and estradiol treatments
Both HCT116 and LoVo cells were purchased from ATCC (Manassas, VA, US). HCT116 cells were maintained in phenol red-free Dulbecco's modified Eagle's medium (DMEM, HyClone, UT, USA) containing 10% fetal bovine serum (FBS, HyClone), 100 U/ml Penicillin G and 100 μg/ml Streptomycin Sulphate (Sigma, St. Louis, MO, US); whereas LoVo cells were maintained in phenol red-free RPMI 1640 medium (HyClone) containing 10% FBS. Both cell lines were cultured in a humidity atmosphere at 37℃, with 5% CO2. In the experiments in which cells were transfected and subsequently treated with or without (controls) estrogen, the cells were cultured as following: Cells were passaged once from frozen stock, and grown in regular 10%FBS (HyClone, UT, USA) for 3 days, followed by another passage and grown for 6 days in 10% charcoal-stripped FBS (Sigma) DMEM (for HCT116) or RPMI 1640 medium (LoVo cells). HCT116 or LoVo cells were transiently transfected with hMLH1, MSH2, and hERβ, respectively, using plasmids pCMV2-hygro-MLH1 (containing full-length wild-type cDNA of hMLH1), pCMV2-hygro-MSH2
(containing full-length wild-type cDNA of hMSH2), and pCMV2-hygro-ERβ (containing full-length cDNA of hERβ). pCMV2-hygro (empty vector) was used as a vehicle control. All vectors and corresponding cDNAs were sequence-validated. Transfection was performed when cells reached 70-80% confluence, using VigoFect transient transfection kit (Vigorous Biotech, Beijing, China) according to the manufacturer's instructions. 24 hours after transfection, cells were incubated with or without (control) 17β-estradiol (E2; Sigma, 10 -8 M) for 24 or 48 hours.
Western blot analysis
The proteins were extracted from the cells or colonic biopsies by RIPA buffer (Sigma, St. Louis, MO, US). Extract proteins (50 μg) were separated by 12% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, probed with 1:1000 dilution of primary antibodies (below), and incubated with FITC-conjugated anti-mouse or anti-rabbit immunoglobulin (1:15000 dilution; Millipore, MA, USA). Primary antibodies used for Western blot analyses include: Anti-hMLH1, -hMSH2, and -ERβ, polyclonal antibodies were purchased from Epitomics (Burlingame, CA, USA); anti-caspase 3 and -caspase 9 were purchased from Cell Signaling Technology (Beverly, MA, USA); anti-Bax, -P53 and -GAPDH monoclonal antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Expression of proteins of interests was imaged using an ODYSSEY quantitative fluorescent imaging system (LI-COR, Lincoln, NE, USA), and quantified by Image StudioTM Lite Western Blot Analysis software (LI-COR, Lincoln, NE, USA).
Flow cytometric analysis
Apoptosis analysis by FACS was performed using Annexin V-FITC/Dead Cell Apoptosis Kit with Annexin V-FITC and PI (Invitrogen, Grand Island, NY, USA) according to manufacture's instructions. HCT116 cells plated in 24-well plates were transfected respectively with hMLH1, hMSH2, and ERβ. 24 hours after transfection, cells were incubated with E2 for 24 or 48 hours. Cells were then harvested and rinsed with cold PBS 3 times and resuspended in the Binding Buffer. To each 100 μl of cell suspension culture, 5 μl of Annexin V-FITC and 1 μl of PI working solution (100 μg/ml) were added. Cells were incubated at room temperature for 15 minutes. After incubation, 400 μl of 1X Annexin-binding buffer was added to the cells and the cells were immediately placed on ice. The cells were analyzed using a BD FACS Calibur flow cytometer (BD Biosciences, San Jose, CA, USA). The percentage of early apoptotic cells (Annexin V+, PI-, the lower right quadrant) was calculated.
Assessment of cell viability
Cell viability was assessed by a tetrazolium-based colorimetric assay using Cell Counting Kit-8 (CCK-8, Takara BIO, Dalian, China), according to the manufacturer's instructions. 24 hours after transfection, cells were seeded in 96-well plates and incubated with 10 -8 M E2 for 48 hours. CCK-8 (10 μl) was then added to each well. After incubation in the dark for 2 hours at 37℃, the optical density (OD) at 450 nm was measured by GENios Pro microplate reader (Tecan, Männedorf, Switzerland). The percent viability was calculated as follows: relative viability
Colonic mucosal samples
Colonic (sigmoid) mucosal biopsies were obtained from 3 healthy female subjects with menopausal syndrome before and after 6-month hormone replacement therapy (HRT) with conjugated equine estrogens (0.3 mg /day). Subjects underwent colonoscopy and MMR before and after HRT. All participating subjects signed informed consents/agreements approved by the hospital ethic committee.
Statistical analyses
Levels of proteins of interest evaluated by Western blot were quantified using Image StudioTM Lite Western Blot Analysis software (LI-COR, Lincoln, NE, USA) and normalized to GAPDH; and statistical analysis between groups was performed using ANOVA. The SPSS 13.0 software was used for statistical analyses of FACS data. P value <0.05 was considered statistically significant. At least 3 independent experiments were performed in each set of data presented.
Results
Effects of hMLH1, hMSH2 or ERβ on the changes of major apoptotic proteins in the presence or absence of estradiol/E2 in HCT116 cells
To evaluate the effects of hMLH1, hMSH2, or ERβ on the apoptotic status of colon cancer cells, we examined several major apoptosis-related proteins, including caspases-3, caspase-9, Bax, and P53 in colon cancer cells with over-expression of various genes of interest ( Figure 1) . Overall, overexpression of hMLH1, or hMSH2, or ERβ significantly increased the activated (cleaved) form caspase-3 and caspase-9, as well as the expression of Bax and P53, when compared with the controls (transfected with empty vector). However, only over-expression of hMLH1, but not hMSH2 or ERβ, resulted in additional E2-dependent activation of caspase-3 and caspase-9, and further enhanced expression of Bax and P53.
Expression of hMLH1, hMSH2 or ERβ decreased the cell viability in the presence or absence of estradiol/E2 in HCT116 cells
First, introducing either hMLH1, or hMSH2, or ERβ into HCT116 cells significantly decreased the cell viability, compared with the vehicle controls, regardless of presence or absence of E2 (Figure 2 ). However, E2-mediated further reduction in cell viability occurred only in cells with overexpression of hMLH1, but not hMSH2 or ERβ (Figure 2) . These results are consistent with the apoptotic data described above.
Apoptosis, measured by FACS with Annexin V-FITC, increased when cells transfected with either hMLH1, hMSH2 or ERβ; however, E2-dependent additional apoptosis occurs only in the in HCT116 cells overexpressing hMLH1
The apoptotic rates were potently enhanced in HCT116 cells transfected with either hMLH1, or hMSH2, or ERβ, compared with the vehicle controls (Figure 3 ). An additional increase in the apoptosis by E2 treatment at 48 hours was observed only in cells with expression of hMLH1 ( Figure 3B & Figure 3C , right panel). There was no effect E2 treatment on apoptosis at 24 hours ( Figure 3A & Figure 3C , left panel). 
Overexpression of hMLH1 in hMSH2-deficient LoVo cells also enhances both basal level and estradiol-induced apoptosis
To provide additional evidence to support the observation in HCT116 cells that the estrogen-dependent pro-apoptotic effect is mediated by hMLH1, not MSH2, we overexpressed hMLH1 in hMSH2-deficient LoVo cells and evaluated the apoptotic status in the presence or absence of estradiol by examining the levels of activated (cleaved) forms of caspase-3 and caspase-9, as well as the expression of Bax and P53 (Figure 4) . Clearly, deficiency of MSH2 in LoVo cells did not affect the E2-mediated enhancement of apoptosis, as E2 potently activated caspase -3 and -9 and increased the expression of P53 and Bax. This would suggest that MSH2 play little role in E2-mediated apoptosis. Importantly, however, overexpression of hMLH1 in LoVo cells promote apoptotic activity even in the absence of E2; and E2 could further enhance the apoptotic activity, as indicated by the increase of cleaved caspase 3 and caspase 9, as well as the expression of Bax and P53. In vivo hormone replacement therapy (HRT) in healthy post-menopausal women led to increased expression of hMLH1, with concurrent elevation of cleaved caspase 3 and caspase 9 in the colonic mucosa
To determine the relevance of our in vitro cell culture data to human subjects in vivo, we investigated if the hMLH1-mediated and estrogen-dependent pro-apoptotic effects observed with colonic epithelial cells could be recapitulated in the colonic biopsies from postmenopausal women after 6-month HRT. As shown in Figure 5 , HRT consistently enhanced the expression of hMLH1, with a significant concurrent increase in the activation of caspase 3 and caspase 9.
Discussion
We present the first evidence, both in vitro and in vivo to demonstrate that the protective role of estrogen in colorectal cancer may be exerted specifically by MMR protein hMLH1-mediated programmed cell death of colon cancer cells. This estrogen-induced apoptosis occurs only through hMLH1, but not hMSH2, although overexpression of either can promote apoptosis.
Accumulating indirect evidence indicates that MMR proteins may involve in estrogen-mediated prevention or delaying of colorectal carcinogenesis. Important in maintaining genomic stability, MMR dysfunction can lead to microsatellite instability (MSI). MSI-high has been shown to be significantly associated with very low levels of estrogen receptor in colorectal carcinoma tissues, suggesting that MMR-deficient tumors might lose an estrogenic modulation mechanism 11 . The fact that postmenopausal HRT reduces risks of only MSI-low/MSI-stable colorectal cancer subtypes further indicates a role of estrogen in colorectal cancer prevention 5 . Moreover, a cohort study has shown that hormone replacement therapy only reduces the risk of MMR-proficient colorectal cancer, but not of MMR-deficient tumors 6 . We have previously demonstrated that estradiol increases the expression of hMLH1 in colonic epithelial cells via ERβ 12, 13 . We now demonstrated here that HRT significantly enhances hMLH1 expression in the colonic biopsies, suggesting that the HRT [conjugated equine estrogens (0.3 mg /day) may work as ERβ-agonist to increase MLH1 expression. MMR protein-dependent pro-death signaling in response to various DNA-damaging agents have been well characterized, including 5-fluorouracil 14, 15 , cisplatin 16, 17 , and methylation agents 18, 19 . However, MMR protein-dependent pro-apoptotic response to estrogen is largely unknown. There are two predominant hypotheses on the MMR protein-dependent initiation of cell death in response to DNA damage 15 . The first hypothesis assumes that the repairing capacity of MMR proteins is required for MMR protein-dependent cell death, while the second suggests that it may not necessarily be required in damage-induced signaling. Since both hMLH1 and hMSH2 are indispensable for DNA mismatch repair function 20 , the fact that overexpression of hMLH1 in hMSH2-deficient LoVo cells could also enhance estradiol-induced apoptosis would strongly suggest that the DNA repair capacity of MMR is not essential for estradiol-induced apoptosis. Moreover, in methylation agent-or cisplatin-induced cells apoptosis, it has been shown that hMSH2 is required for the formation of either hMSH2/hMSH6 or hMSH2/hMSH3 heterodimer that recognizes the DNA damage and subsequently triggers pro-death signaling 16, 21 . However, our study demonstrated that estrogen-induced apoptosis of colonic cancer cells was mediated by hMLH1, but not hMSH2. Our data support a distinct role of MMR proteins in estrogen-induced apoptosis vs DNA-damaging agent-mediated cell death.
How estrogen/estradiol, which is not a DNA-damaging agent, can induce programmed cell death? Although the mechanism is not well understood, certain metabolites of estrogen have been shown to enhance the rate of oxidative DNA damage in breast and endometrial cells 22, 23 , suggesting a possible role of estrogen in potentiating oxidative cytotoxicity. However, we do not believe this is the mechanism how estrogen enhances hMLH1-dependent apoptosis in colon cancer cells because if it is, overexpression of MMR protein hMLH1 would have promoted DNA repair, thereby decreasing apoptosis. Therefore, the exact molecular mechanism by which estrogen induces apoptosis through hMLH1 remains to be elucidated.
ERβ is the predominant ER in the human colonic epithelium and its expression decreases during colon carcinogenesis 24, 25 . Lack of ERβ expression is associated with loss of differentiation and decreased apoptosis 26 . We demonstrate that overexpression of ERβ in HCT116 cells spontaneously induces apoptosis that is independent of estrogen. Together with our hMLH1 and hMSH2 data, our study strongly supports previous reports that ERβ induces an extensive anti-tumorigenic effect in colon cancer cells through perhaps interaction with the DNA repair and p53 genes 27, 28 .
Our in vivo study with healthy postmenopausal female subjects demonstrates that HRT could significantly enhance the apoptosis in the colonic biopsies, as indicated by the robust activation of caspase 3 and caspase 9. Previous reports have demonstrated that estrogen induces apoptosis in malignant and non-malignant colonocytes of human or rodents [28] [29] [30] [31] [32] [33] . Various mechanisms of action have been proposed, including p53-mediated signaling 28, 30, 32 , increased Bax expression 33 , and decreased Bcl-2 31 . Moreover, overexpression of hMLH1 or hMSH2 could induce apoptosis in either MMR-proficient or -deficient cells 34 , indicating that hMLH1 and hMSH2 may play a similar or redundant role in enhancing apoptosis through increased expression. This observation has also been validated in our studies using both HCT116 and LoVo cells. Interestingly, however, our study revealed that hMLH1 also mediated estrogen-induced apoptosis that is distinctively different from hMSH2, as lack of or overexpression of hMSH2 has no significant influence on estradiol-induced apoptosis. Mechanism dictating these distinctive functions is currently unknown. It is possible that hMSH2 may have other unrecognized functions unrelated to estrogen regulation, as it has been shown to interact with ERβ in a ligand-independent manner 35 .
In summary, we present compelling evidence that, while increased expression of MMR protein, either hMLH1 or hMSH2, promotes apoptosis in colonic cancer cells, estrogen-induced apoptosis of these cells is mediated by hMLH1, but not hMSH2. Our human colonic mucosal biopsies data demonstrate that a 6-month HRT can potently enhance hMLH1 expression and concurrently activate apoptosis in vivo. Considering the previous reports that HRT-mediated reduction on the risk of colorectal cancer is dependent on MSI status 5, 6 , these findings have important implications for clinical practice: MMR status should be evaluated in patients being considered for hormone replacement therapy or in the future application of estrogen-based chemoprevention against colorectal cancer to maximize the benefit/risk ratio.
